BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral

EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes

May 9, 2016 4:00 PM EDT

New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator sales estimated in 2020Amit Munshi steps down as president and chief executive officer; Dr. Scott Rocklage, founding chief executive officer of Cubist and currently a company director appointed as chief executive officer and Dr. Michael Wyand named president and chief operating officer

BOSTON, May 09, 2016 (GLOBE NEWSWIRE) --... More